A Phase 1 interventional study of Abemaciclib and Clarithromycin in Neoplasm and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing abemaciclib in Neoplasm Metastasis — 3 open to participants now, 8 under way, 3 of them phase 3. abemaciclib · Neoplasm Metastasis.
Among the 15 studies testing abemaciclib in Neoplasm Metastasis, this one is the 11th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 2nd registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.
Browse Neoplasm Metastasis studies →3 of the 15 studies testing abemaciclib in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+ · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–90 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 48 across the 15 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
72 studies in Neoplasm Metastasis by Eli Lilly and Company: 7 open now, 16 under way, 7 of them phase 3. Of 54 finished, 37 (69%) have results posted.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 53rd largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2014, is one of 43 in phase 1, and was the 39th registered.
Eli Lilly and Company’s Neoplasm Metastasis studies by the year they started, since 2002.
2 of the studies testing abemaciclib in Neoplasm Metastasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07441369Fudan UniversityAbemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | 2027-04-30 |
| NCT05095207Icahn School of Medicine at Mount SinaiAbemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing abemaciclib in Neoplasm Metastasis, from their registry updates:
Among Eli Lilly and Company’s 72 in Neoplasm Metastasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied.
Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.
This study's enrollment of 26 is below the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
Drug: Abemaciclib
Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
Drug: Abemaciclib · Drug: Clarithromycin
After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
Drug: Abemaciclib
Administered orally
Also known as: LY2835219
Administered orally
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib
Time frame: Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
PK: Maximum Concentration (Cmax) of Abemaciclib
Time frame: Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96,120,144,168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
| Milestone | Abemaciclib Alone Then Abemaciclib + Clarithromycin |
|---|---|
| Started | 26 |
| Received at least 1 dose of study drug | 26 |
| Completed | 24 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Abemaciclib Alone Then Abemaciclib + Clarithromycin |
|---|---|
| Started | 24 |
| Received at least 1 dose of study drug | 21 |
| Completed | 20 |
| Not completed | 4 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Death | 1 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Abemaciclib Alone Then Abemaciclib + Clarithromycin |
|---|---|
| Started | 20 |
| Completed | 0 |
| Not completed | 20 |
| Withdrew: Progressive disease | 12 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 3 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 2 |
| nanogram*hour/milliliter(mL) ng*h/mL | Abemaciclib Period 1 | Abemaciclib + Clarithromycin Period 2 |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib | 2230 ± 93 | 6850 ± 66 |
| nanogram/milliliter (ng/mL) | Abemaciclib Period 1 | Abemaciclib + Clarithromycin Period 2 |
|---|---|---|
| PK: Maximum Concentration (Cmax) of Abemaciclib | 70.0 ± 73 | 84.3 ± 55 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib | — | 1/26 (3.8%) | 13/26 (50%) |
| Clarithromycin | — | 1/24 (4.2%) | 7/24 (29.2%) |
| Abemaciclib + Clarithromycin | — | 1/21 (4.8%) | 10/21 (47.6%) |
| Safety Extension Abemaciclib | — | 15/20 (75%) | 19/20 (95%) |
| Event | Abemaciclib | Clarithromycin | Abemaciclib + Clarithromycin | Safety Extension Abemaciclib |
|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 3/20 |
| Atrial fibrillationCardiac disorders | 0/26 | 0/24 | 0/21 | 2/20 |
| AnaemiaBlood and lymphatic system disorders | 0/26 | 0/24 | 1/21 | 1/20 |
| Sinus tachycardiaCardiac disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| Abdominal painGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| AscitesGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| NauseaGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| VomitingGastrointestinal disorders | 0/26 | 0/24 | 0/21 | 1/20 |
| Event | Abemaciclib | Clarithromycin | Abemaciclib + Clarithromycin | Safety Extension Abemaciclib |
|---|---|---|---|---|
| FatigueGeneral disorders | 1/26 | 1/24 | 1/21 | 14/20 |
| AnaemiaBlood and lymphatic system disorders | 3/26 | 0/24 | 2/21 | 12/20 |
| DiarrhoeaGastrointestinal disorders | 0/26 | 0/24 | 1/21 | 12/20 |
| NauseaGastrointestinal disorders | 3/26 | 1/24 | 1/21 | 9/20 |
| Neutrophil count decreasedInvestigations | 0/26 | 1/24 | 0/21 | 9/20 |
| Blood creatinine increasedInvestigations | 2/26 | 0/24 | 1/21 | 8/20 |
| HypokalaemiaMetabolism and nutrition disorders | 0/26 | 0/24 | 1/21 | 8/20 |
| VomitingGastrointestinal disorders | 1/26 | 2/24 | 1/21 | 7/20 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/26 | 0/24 | 0/21 | 5/20 |
| Abdominal painGastrointestinal disorders | 2/26 | 0/24 | 1/21 | 4/20 |
| Age, Customized(years) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| Mean | 60.0 ± 9.2 |
| Sex/Gender, Customized(Participants) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| Female | 19 |
| Male | 7 |
| Race/Ethnicity, Customized(Participants) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 25 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| United States | 26 |
| Body Mass Index (BMI)(kilogram/square meter (kg/m2)) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| Mean | 27.62 ± 6.04 |
| Eastern Cooperative Oncology Group (ECOG) Scale(participants) | Abemaciclib Then Abemaciclib + Clarithromycin |
|---|---|
| ECOG= 0 | 18 |
| ECOG= 1 | 8 |
The record gives a start of Apr 2014, a primary completion of Feb 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib